FY2028 Earnings Estimate for TSE:ONC Issued By HC Wainwright

Oncolytics Biotech Inc. (TSE:ONC) – Research analysts at HC Wainwright dropped their FY2028 earnings per share (EPS) estimates for Oncolytics Biotech in a research report issued on Wednesday, May 21st. HC Wainwright analyst P. Trucchio now forecasts that the company will earn $0.56 per share for the year, down from their previous forecast of $0.57. The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Oncolytics Biotech’s FY2029 earnings at $1.03 EPS.

Separately, Jones Trading downgraded shares of Oncolytics Biotech from a “strong-buy” rating to a “hold” rating in a research report on Friday, May 16th.

Oncolytics Biotech Trading Down 3.3%

TSE ONC opened at C$0.58 on Thursday. The company has a quick ratio of 8.86, a current ratio of 2.99 and a debt-to-equity ratio of 11.75. The stock’s 50 day moving average is C$0.77 and its 200 day moving average is C$1.06. The firm has a market capitalization of C$44.70 million, a PE ratio of -1.62 and a beta of 1.35. Oncolytics Biotech has a twelve month low of C$0.57 and a twelve month high of C$2.08.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.